is an Australian company, specialising in the development of monoclonal antibody therapies for multiple myeloma and other blood cancers. Multiple myeloma is a fatal blood cancer that affects more than 100,000 patients worldwide.

IST has considerable expertise in the genetic engineering of monoclonal antibodies based on more than ten years of research conducted at the University of Technology, Sydney.

IST's lead antibody therapy is designed to target specifically and kill multiple myeloma cells. It does not target healthy cells, which means there should be few side effects. If successful, it would have significant advantages over existing cancer treatments, resulting in extended and improved quality of life for sufferers.

There are two types of multiple myeloma. IST's lead product for the treatment of the most common type of multiple myeloma is in the late pre-clinical phase of development. IST has also commenced development of an antibody designed to treat patients with a less common type of multiple myeloma, and is evaluating the effect of its monoclonal antibodies on other lymphoproliferative disorders.

IST has a strong management team, with a proven track record of commercialising technology, and a talented drug development group that has significantly advanced the development of its lead therapeutic.

"...the latest generation of Mabs represents the biggest growth area in biotech today."
DNA The Secret of Life, p.126
James D Watson, 2003